Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη μοριακών παραμέτρων στον καρκίνο του θυρεοειδούς για την αναγνώριση δεικτών πρόβλεψης ευαισθησίας σε στοχευμένη θεραπεία

Abstract

dc:description

The aim of the present study was to investigate the molecular pathways and individual molecules involved in thyroid carcinogenesis in order to identify potential diagnostic markers, as well as markers predictive of sensitivity to specific therapeutic inhibitors (small molecule tyrosine kinase inhibitors, TKIs). The selected molecules are involved in molecular pathways that have been reported to exhibit genetic/functional changes in thyroid cancer and represent pharmaceutical targets. Materials and methods: Twenty cell lines and 220 patient samples were studied, out of which 139 had been classified as papillary carcinomas (PTC), 16 as follicular (FTC), 34 as myeloid (MTC), 14 were anaplastic (ATC), 11 poorly differentiated (PDTC) and 5 were non-cancerous thyroid tissue (NCTT). Genotypic analysis was carried out utilising both Real Time PCR and direct sequencing. Furthermore, the relative mRNA expression of EGFR and HER2 and their alternatively spliced isoforms, as well as the relative expression of HSP90 and the mRNAs of genes related to it, and genes encoding proteins associated with angiogenesis, was evaluated. Also, the expression of three miRNAs (MIRN146b, MIRN221, MIRN222), which seem to be associated with thyroid cancer, was studied, using in situ hybridisation and Real Time PCR. In addition, the effect of two of tyrosine kinase inhibitors [Vandetanib (ZD6474, Zactima™, AstraZeneca, Wilmington, DE) and Sunitinib (SUI 1248, Sutent®, Pfizer, New York, NY)] in thyroid cancer cell lines was studied. Results: BRAF V600E mutation was present in 38% of thyroid cancer samples (50.8% of papillary thyroid carcinomas), while RET/PTC rearrangements, were detected in only 8.33% of samples. Differences in the relative expression of EGFR were observed when using probes targeting different regions of the EGFR mRNA (amplicons for exons 10-11 and 15-17). Anaplastic carcinomas appear to have significantly different expression profiles of HER2 and var3 of EGFR compared to non-cancerous tissue (p = 0.006 and p = 0.00105, respectively), with HER2 exhibiting an increase in relative expression, whereas EGFR var3 expression appeared downregulated. RET kinase does not appear to be expressed in most tissue types studied, with the exception of medullary carcinomas. Significant differences were observed in expression profiles between tissue samples and cell lines, for almost all the molecules studied. Only thyroid carcinomas were positive for all 3 miRs studied (p < 0.00001 compared with tumours of different histological origin). Moreover, among thyroid carcinomas, overexpression of all 3 miR was significantly more frequent in PTCs compared with MTCs (p = 0.007) and ATCs (p = 0.0001). The two tyrosine kinase inhibitors investigated seemed to inhibit cell proliferation but did not ultimately lead to apoptosis. A transient inhibition in the phosphorylation of MEK and MAP kinases was also observed, as well as a change in the relative expression of DUSP6 (dual specificity phosphatase 6) and THBS1 (thrombospondin 1). However, no synergy with other chemotherapeutic agents was observed. Conclusions: BRAF V600E mutation is characteristic for PTC, but its incidence does not permit its use as a diagnostic test. The observed differences in anaplastic carcinomas on expression profiles of EGFR/HER2 and their splice variants, which are known to be endogenous HER inhibitors, should perhaps be taken into account when designing studies on the use of exogenous HER inhibitors. Furthermore, ATC appear to have a characteristic angiogenic factor expression profile, which September suggest an association with their aggressive behaviour and September also constitute a target for pharmacological inhibition. PTC and MTC on the other hand, are characterized by changes in HSP90 related mRNA expression, pointing to a role of these genes in the progression of tumors with corresponding histology. From a technical point of view, the choice of probe, as well as the position of its binding site on the mRNA, appears to be determinative for the evaluation of relative gene expression. Overexpression of miRsl46b/221/222 appears to characterize PTC. The miR in situ hybridisation method applied in this study could be used for further investigation of these miRs, and could eventually be integrated as a diagnostic tool in cytologic specimens. The tyrosine kinase inhibitors vandetanib and sunitinib inhibit cell proliferation in vitro, but do not lead to apoptosis. They seem to transiently inhibit MAP and MEK kinase phosphorylation, possibly through DUSP6 phosphatase intervention. This mechanism appears to have special significance and should be further investigated.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Charalambous, Elpida
  • Χαραλάμπους, Ελπίδα

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/24740

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Charalambous, Elpida; Χαραλάμπους, Ελπίδα. Μελέτη μοριακών παραμέτρων στον καρκίνο του θυρεοειδούς για την αναγνώριση δεικτών πρόβλεψης ευαισθησίας σε στοχευμένη θεραπεία. Aristotle University Of Thessaloniki (AUTH), 2011. http://hdl.handle.net/10442/hedi/24740